Hepatitis C market enters the fast lane scale, attractive drugs need to be refreshed April 13, 2015 Source: Medical Network Hepatitis C market enters fast lane
POE (Power Over Ethernet) refers to the use of IP-based terminals (such as IP telephones, wireless LAN access points, and network cameras) without any changes to the existing Ethernet Cat.5 cabling infrastructure. etc.) The technology that can provide DC power for such devices while transmitting data signals is a switch that supports Power over Ethernet.
At the same time, POE is also called Power over LAN (POL, Power over LAN) or Active Ethernet, sometimes referred to as Power over Ethernet, which uses existing standard Ethernet transmission cables to transmit data at the same time and the latest standard specifications for electrical power and maintain compatibility with existing Ethernet systems and users.
We will provide different solutions for different customers, we can provide 4+2 Ports, 8+2 Ports, 16+2 Ports, 24+2 Ports and 48+2 Ports POE switches, if you want to know more details ,please feel free to contact us.
The advantages of our 16+2 Ports POE switches are as follows:
1. Low insertion loss
2. Low voltage protection level
3. Quick response, high transmission speed
4. Available with 16 ports RJ45 connection
5. Average fault-free working for 100,000 hours
We are a factory specializing in the production, manufacture and research and development of intercom system and Accessories with 11 years experience. We are located in the beautiful coastal city - Zhuhai China. We can provide professional products.competitive price.great services. We have different products for different customers and markets, if you are interested, please feel free to contact me, I can send our catalog to your email.
FAQ
Q: What is the lead time ?
A: It will take 7-15 days in normal season, customization products will take 15-30days.
Q: Can i have some samples?
A: Sure,sample are available, pls feel free to contact with us if you need some samples.
Q: What is the sample time?
A: It takes 3-5 days.
Q: Is OEM/ODM service?
A: Yes, we can provide OEM and ODM service.
Q: What is your MOQ?
A: We can accept a small order
Q: Can you tell me the price?
A: We quote within 24 hours after receiving your inquiry
Q: Why are you choosing us?
A: We are manufacturer with 11 years experience and we can offer you with professional service and competitive price. If you want to know about us ,pls feel free to contact with us.
16+2 Port Poe Switch,16 Port Managed Switch,16 Port Poe Switch,16 Port Poe Zhuhai Mingke Electronics Technology Co., Ltd , https://www.zhmkdz-electronics.com
Hepatitis C market enters the fast lane scale, attractive drugs need to be refreshed
Just past the National Love Liver Day, the theme is "preventing hepatitis C and preventing it from happening". Because most patients with hepatitis C have almost no symptoms or mild symptoms in the early stage, the liver function indicators of biochemical tests are basically normal, which leads many patients to be unaware of their illness, and the discovery rate and treatment rate are very low. When the symptoms of liver discomfort, anorexia, jaundice and other symptoms appear, the condition basically enters the middle and late stage, and the most effective time for treatment has been lost. Once infected with hepatitis C virus (HCV), only 5% to 10% of patients infected with hepatitis B will develop chronic, and 60% to 80% of hepatitis C infection will be converted into chronic hepatitis C, eventually leading to liver inflammation. Liver fibrosis, cirrhosis and liver cancer.
Hepatitis C is a "hidden killer" that is extremely harmful. In the United States, chronic hepatitis C is the leading cause of liver cancer and liver transplantation, and approximately 15,000 patients die each year from HCV-related diseases, exceeding HIV/AIDS. The cost of medical insurance in the United States in the field of hepatitis C disease is extremely large.
In China, the 2013 Statistical Yearbook shows that the incidence rate of hepatitis C in 2012 was 14.96/100,000, calculated according to the population of 1.3 billion, and the number of cases was about 194,000, which is an increase from the reported number of cases in 2010. 21.6%. However, according to a recent World Health Organization report, the incidence of hepatitis C in China is 3.2%, which is equivalent to about 40 million patients with hepatitis C.
The difference between the predicted number of patients and the actual patients is due to the fact that the disease is occult, and there are many reasons such as a certain window period, unstable results of hepatitis C antibody detection reagents and a small number of infected persons not producing antibodies, and cannot completely screen out hepatitis C virus. RNA positive. On the other hand, it is also due to the public's indifference to it. A survey of hepatitis C showed that the public's awareness of hepatitis C was only 38%, far lower than hepatitis A (91%) and hepatitis B (95%). At the same time, only 1% of the respondents had a correct understanding of the transmission route and preventive measures of hepatitis C, and 76% of the respondents did not understand that hepatitis C can be cured. The above reasons caused the market to initially calm, and as the latent virus began to attack, the market began to enter the fast lane.
Attractive market size
Since there is no preventive vaccine for hepatitis C, it is not as good as hepatitis B in the effective implementation of preventive vaccine. The only effective is to screen hepatitis C in the early stage, and early detection of timely treatment can be cured by 60% to 80%.
The current clinical treatment for hepatitis C is a combination of interferon plus ribavirin. The US pharmaceutical and healthcare products market research firm Decision Resources predicts that China's HCV market value will increase from 137 million US dollars in 2010 to 247 million US dollars in 2015, which translates into a market capacity of about 1.5 billion yuan. The huge population of hepatitis C patients, the expansion of government-led universal medical insurance coverage and the high treatment costs of major diseases are gradually included in the trend of medical insurance reimbursement, making the growth potential of China's hepatitis C market full.
2013 global hepatitis C market size of about $ 4.7 billion in Gilead hepatitis C drug Sovaldi Pharmaceuticals (sofosbuvir) is a potent stimulator of 2014 hepatitis C market is impressive, so many businesses were Encouraged, they began to compete to develop all-orbital hepatitis C treatment drugs, and at the same time turned their attention to the Chinese market with a large number of patients.
Hospital competition concentration
From the sample hospital data, ribavirin currently has nearly 80 competitors, of which Shanghai Xinyi leads the market with 42.0%, and Jiangsu Tianji Pharmaceutical ranks second with less than half of the former. Its main sales areas are in Beijing and Guangzhou. The top five manufacturers accounted for 78.6% of the total, and the market concentration was high.
There are five main types of interferon used in the treatment of hepatitis C: peginterferon alfa-2a, peginterferon alfa-2b, recombinant human interferon alpha-1b, recombinant human interferon alpha-2b Recombinant human interferon α-2a, in which pegylated interferon α-2a (trade name: PEGASYS) belongs to the exclusive variety of Roche Pharmaceuticals, was listed in China in 2003, and now accounts for the hepatitis C treatment interferon in the sample hospital. Half of the market (see photo), Schering-Plough's peginterferon alfa-2b (trade name: PegIntron) also has a 17.7% market, followed. Recombinant human interferon alpha-2b is the most common producer of these interferons. Except for Schering-Plough's Ganle, which belongs to foreign-funded enterprises, the others are domestic enterprises.
Gilead's oral hepatitis C drug Sovaldi has been on the market for a while, but with its turbulent market, many oral competitors are on the market. Coupled with the new triple therapy at this stage, I believe that more new drugs will refresh the drug market in the near future.